Non in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... +27% non GAAP operating income $116 ... $35 million +$102 million non GAAP diluted earnings per ADS (using actual Q2 ... $0.60 -36% non GAAP diluted earnings per ADS (using full year ...

Shire begins the year with a strong performance

... +32% non GAAP operating income ... $226 million +39% non GAAP diluted earnings per ADS ... 2008 non Non US ...

BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results

... Corporation and Subsidiaries non GAAP Condensed Consolidated Statements of ... and Subsidiaries non GAAP Reconciliations ($ ... 129 -- 1,014 -- non GAAP Gross Profit $19,329 $ 1,483 ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... $3.02bn + 24% $0.77 bn + 6% non GAAP diluted earnings per ADS ... delivered a strong performance in 2008: - non GAAP diluted earnings per ADS up 36%; - New ... 2007 non Non ...

January 2009 - Rahu Appoints David Greensmith to Non Executive Directo

... ) David holds a number of other non executive positions including Chairman of One ... in Tropical Health, Chairman of MatOx Ltd and non Exec Director of the Warwick International Group ... contact details are: David Greensmith non Executive Director Rahu Catalytics Limited ...

BMP Sunstone Reports Third Quarter 2008 Financial Results

... BMP Sunstone Corporation and Subsidiaries non GAAP Condensed Consolidated Statements of ... $80,923 non GAAP Reconciliations ($ amounts, ... 109 -- 885 -- non GAAP Gross Profit $13,936 ...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... 22%) - Total revenues up 28% to $779 million - non GAAP earnings(2) per ADS up 88% to $1.17 (2007: ... its business. Product sales were up 31% and non GAAP earnings per ADS rose 88%, compared with ... Q3 2007 non ...

New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence

... Ability of Pleth Variability Index to non Invasively Predict the Hemodynamic Effects of ... (3) Ability of Pleth Variability Index to non Invasively Predict the Hemodynamic Effects of ... UCLA, Los Angeles, California. (6) PVI A non invasive device for fluid responsiveness. ...

Lotus Pharmaceuticals Announces Second Quarter 2008 Results

... 0.06 3,389,362 0.08 Adjustments non cash debt financing costs (1) ... 2,179,909 0.05 3,041,525 0.07 (1) non cash debt financing costs for Q2 2008 includes ... redeemable preferred stock of $254,129; non cash debt financing costs for Q2 2007 ...

China Biologic Products Reports Second Quarter 2008 Results

... of 2007. The six-month net income was impacted by non cash employee compensation and ... EPS Net Income EPS Adjusted Amount - non GAAP $3,297,342 $0.15 $3,443,500 ... EPS Net Income EPS Adjusted Amount - non GAAP $5,565,142 $0.26 $5,342,343 ...

BMP Sunstone Reports Second Quarter 2008 Financial Results

... in thousands, except per share amounts) non GAAP Net Income (Loss) ... Sunstone Corporation and Subsidiaries non GAAP Condensed Consolidated Statements of ... $80,923 non GAAP Reconciliations ($ ...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

... per ADS: loss $0.44 (2007: loss $9.93) - non GAAP earnings per ADS up 70% to $0.95 (2007: ... Q2 2007 US non US non GAAP Adjustments GAAP(1) ...

Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests

... at Parkway's facility are: - Squamous vs. non Squamous non-small cell lung cancer - This test is designed to differentiate squamous from non squamous non- small cell lung cancer (NSCLC) ... Certain angiogenesis inhibitors for non-squamous non small cell lung cancer (NSCLC) include a ...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... test is designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) and ... Diagnostic Programs - Squamous vs. non Squamous non-small cell lung cancer (NSCLC) ... test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using ...

Rosetta Genomics Reports First Quarter 2008 Financial Results

... test is designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) and ... Diagnostic Programs - Squamous vs. non Squamous non-small cell lung cancer (NSCLC) ... test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using ...

Pharsight Achieves $7.6 Million In Quarterly Revenue

... CORPORATION RECONCILIATION OF GAAP TO non GAAP FINANCIAL MEASURES (in ... (Unaudited) Net income - non GAAP Three Months Ended ... ------------- ------------- Net income - non GAAP $995 $1,104 ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

... - US GAAP Operating income up 15% to $163m - non GAAP Operating income up 23% to $192m - US GAAP Earnings per ADS up 7% to $0.68 - - non GAAP Earnings per ADS up 5% to $0.74 (1) New ... succeed Dr James H Cavanaugh as the Company's non executive Chairman and Angus Russell will succeed ...

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

... - TG4010 (MVA-MUC1-IL2) for the treatment of non small cell lung cancer in combination with ... passive immunotherapeutics, either specific or non specific. The company intends to disclose details ... licences (+ EUR 0.5m); and - An increase in non cash expenses of EUR0.5m (amortization of ...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

... $725m - non GAAP Earnings per ADS up 38% to - non GAAP Earnings per ADS up $2.95 ... 2006 non ...

Pharsight Achieves $7.4 Million in Quarterly Revenue

... CORPORATION RECONCILIATION OF GAAP TO non GAAP FINANCIAL MEASURES ... (unaudited) Net Income - non GAAP Three Months Ended ... -------- -------- Net income - non GAAP $878 $698 $1,945 ...

Beckman Coulter Announces First Quarter 2009 Results

... gains and losses related to operating cash flows, moving these items from non operating expense to cost of sales from non operating expense to cost of sales for both periods. While gross profit ...

Pharmos Corporation Reports 2008 Fourth Quarter Results

... to the decrease in consulting and professional fees in 2008 result from non recurring 2007 costs related to contractual payment obligations associated ... in 2007, a one time IRS section 382 tax analysis cost incurred in 2007, a non recurring recruitment fee in 2007 and higher board fees and travel costs ...

Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS

... Rosetta Genomics' miRview(TM) squamous, which differentiates squamous from non squamous non small cell lung cancer, with available immunohistochemistry methods. ...

China Biologic Products Reports Strong Third Quarter 2008 Results

... Diluted EPS Net Income EPS Net Income EPS Adjusted Amount - non GAAP $4,499,159 $0.21 $2,258,514 $0.11 Non-cash employee ... Diluted EPS Net Income EPS Net Income EPS Adjusted Amount - non GAAP $10,064,301 $0.46 $7,600,857 $0.35 Non-cash employee ...

Five New Clinical Studies Show Value of Masimo PVI & PI

... p.m., Room Hall E2-Area M Ability of Pleth Variability Index to non Invasively Predict the Hemodynamic Effects of PEEP(2)-A1608, Presented: ... VAHS, Long Beach, California. (2) Ability of Pleth Variability Index to non Invasively Predict the Hemodynamic Effects of PEEP. Olivier Desebbe, M.D., ...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

... test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University ...

Pharmos Corporation Reports 2008 First Quarter Results

... 2008. The decrease in consulting and professional fees in 2008 result from non recurring 2007 costs related to contractual payment obligations associated ... chief executive officer, higher legal and accounting fees in 2007 and a non recurring recruitment fee of $42,000 in 2007. Net Operating Loss ...

Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007

... increased by approximately 4%. Non-GAAP operating loss, which excludes non cash charges attributed to SFAS 123 (R) stock options, and depreciation ... following table reconciles our non-GAAP financial measures that exclude non cash charges attributed to stock options under SFAS 123 (R), and ...

NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance

... upon the achievement of certain revenue milestones. Although the sale is non recourse, under U.S. generally accepted accounting pronouncements this transaction will be treated as debt. NPS also issued $100 million of non recourse Sensipar backed B bonds, and issued $50 million of new 5.75% ...

Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results

... 141,311 (0.22) (222,409) (0.26) (1) non cash expense related to debt issue costs (2) non cash expense related to costs of amortization of convertible ...

Microbix Sales Grow 22% For Nine Months

... by licensing partners. Capital expenditures will decline as major investments are completed. Pipeline projects are going to be financed through non dilutive agreements with partners. Microbix continues its corporate restructuring to conserve cash and eliminate its burn rate in order to ensure its ...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... upfront payment and $4.7 million of research revenue on reimbursed research and development costs. The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3 and are primarily due to pre-tax stock compensation expense. Use of Non-GAAP ...

Jatropha Couple Oil Crop Cultivation Technology Commercially Released

... oil seeds and research activities thereon & provides support/services from "Soil to Oil" for development and establishment of the non -food Bio-fuel crops. CJP use its proprietary knowledge to implement programmes through its expertise, technology and IPR knowledge creating new ...

Global Jatropha Hi-Tech Agricultural Training Programme (JWTP)

... oil seeds and research activities thereon & provides support/services from "Soil to Oil" for development and establishment of the non -food Bio-fuel crops. CJP use its proprietary knowledge to implement programmes through its expertise, technology and IPR knowledge creating new ...

Phase 3 Cystic Fibrosis Trial Results Presented at European Conference

... (PDPE) per subject for the 26 weeks was lower for Bronchitol versus control: overall reduction in rate of 25% (p=0.2). -- There was a non significant increase in time to first PDPE (p=0.1) for the Intention to Treat group, however, for the Per Protocol population, i.e. ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... 822 458 2,659 1,144 Prepaid and other 482 446 21,354 20,310 non current assets 1,584 1,356 Shareholders' equity 20,279 20,522 ...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

... diphtheria toxoid, is a contraindication to its use. Prevenar does not provide 100% protection against vaccine serotypes or protect against non vaccine serotypes. The decision to administer Prevenar should be based on its efficacy in preventing invasive pneumococcal disease (IPD). ...

Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma

... trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit. StemEx(R) is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA ...

PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting

... to second generation therapeutic proteins. PAREXEL International--Booth #1701 A complimentary white paper, entitled "Best Practices: non Clinical Trial Safety," will be provided at PAREXEL's Booth #1701. A global team of PAREXEL experts will be available for on-site exclusive executive ...

Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform

... oil seeds and research activities thereon & provides support/services from "Soil to Oil" for development and establishment of the non -food Bio-fuel crops. CJP use its proprietary knowledge to implement programmes through its expertise, technology and IPR knowledge creating new ...